- Home
- HOWL vs IMMX Comparison
HOWL vs IMMX Comparison
Compare HOWL & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOWL
- IMMX
- Stock Information
- Founded
- HOWL 2017
- IMMX 2014
- Country
- HOWL United States
- IMMX United States
- Employees
- HOWL N/A
- IMMX 21
- Industry
- HOWL Biotechnology: Pharmaceutical Preparations
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- HOWL Health Care
- IMMX Health Care
- Exchange
- HOWL Nasdaq
- IMMX Nasdaq
- Market Cap
- HOWL 50.3M
- IMMX 54.9M
- IPO Year
- HOWL 2021
- IMMX 2021
- Fundamental
- Price
- HOWL $1.20
- IMMX $2.39
- Analyst Decision
- HOWL Strong Buy
- IMMX Strong Buy
- Analyst Count
- HOWL 3
- IMMX 1
- Target Price
- HOWL $8.33
- IMMX $7.00
- AVG Volume (30 Days)
- HOWL 643.1K
- IMMX 360.1K
- Earning Date
- HOWL 05-08-2025
- IMMX 06-10-2025
- Dividend Yield
- HOWL N/A
- IMMX N/A
- EPS Growth
- HOWL N/A
- IMMX N/A
- EPS
- HOWL N/A
- IMMX N/A
- Revenue
- HOWL $1,143,000.00
- IMMX N/A
- Revenue This Year
- HOWL N/A
- IMMX N/A
- Revenue Next Year
- HOWL $900.00
- IMMX N/A
- P/E Ratio
- HOWL N/A
- IMMX N/A
- Revenue Growth
- HOWL N/A
- IMMX N/A
- 52 Week Low
- HOWL $0.60
- IMMX $1.26
- 52 Week High
- HOWL $5.73
- IMMX $2.71
- Technical
- Relative Strength Index (RSI)
- HOWL 61.01
- IMMX 62.87
- Support Level
- HOWL $1.18
- IMMX $1.89
- Resistance Level
- HOWL $1.31
- IMMX $2.47
- Average True Range (ATR)
- HOWL 0.11
- IMMX 0.17
- MACD
- HOWL 0.02
- IMMX 0.01
- Stochastic Oscillator
- HOWL 68.83
- IMMX 81.97
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.